A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry

被引:11
|
作者
Bathum, L
Hansen, TS
Horder, M
Brosen, K
机构
[1] Odense Univ Hosp, Dept Clin Biochem, DK-5000 Odense C, Denmark
[2] Odense Univ, Dept Clin Pharmacol, DK-5230 Odense, Denmark
关键词
CYP2C19; genotyping; genetic polymorphism;
D O I
10.1097/00007691-199802000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
CYP2C19 (S-mephenytoin hydroxylase) is a polymorphically expressed enzyme. Currently, two defective alleles are known-CYP2C19*2 and CYP2C19*3. The authors have developed an oligonucleotide ligation assay to detect these two alleles. This assay combines the hybridization of one common, biotinylated capture probe and two allele-specific probes to the target DNA, with the ability of a DNA ligase to distinguish mismatched nucleotides. The probes are only ligated if they are base paired correctly to the target strand. The biotin is bound to streptavidin, and all DNA not covalently bound to the biotin-labeled capture probe, is removed in a washing procedure. The allele-specific probes are labeled with either europium or samarium, and their emission can be measured simultaneously. The ratio between the emission separates the genotypes. This method was applied on DNA from 19 whites and 21 Vietnamese living in Denmark. All genotypes determined by the assay were consistent with the results from restriction enzyme cleavage. There were 12 poor metabolizers; 10 homozygous CYP2C19*2/CYP2C19*2, one heterozygous CYP2C19*2/CYP2C19*3, and one heterozygous CYP2C19*1/CYP2C19*2. The authors conclude that this assay is well-suited for a high throughput of samples in a routine laboratory. The finding of an apparently heterozygous CYP2C19*1/CYP2C19*2 poor metabolizer, confirms that there are still unknown mutations in CYP2C19.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [1] DISTRIBUTION OF THE CYP2C19*2, CYP2C19*3 AND CYP2C19*4 GENE VARIANTS IN A ROMANIAN POPULATION
    Buzoianu, A. D.
    Trifa, A. P.
    Popp, R. A.
    Militaru, C. F.
    Bocsan, C., I
    Popp, I., V
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 80 - 80
  • [2] CYP2C19*2 and CYP2C19*3 allelomorphism in Turkish population
    Dogan, Ali
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 239 : 12 - 12
  • [3] Assessment of CYP2C19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles
    Kim, K. -A.
    Song, W. -K.
    Kim, K. -R.
    Park, J. -Y.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (06) : 697 - 703
  • [4] Rapid CYP2C19 Genotype Testing: Comparison between Spartan RX CYP2C19 and Verigene CYP2C19
    Zhou, Y.
    Armstead, A. R.
    Coshatt, G. M.
    Brott, B. C.
    Sankaranarayanan, A.
    Limdi, N. A.
    Harada, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 845 - 845
  • [5] Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin
    Ibeanu, GC
    Goldstein, JA
    Meyer, U
    Benhamou, S
    Bouchardy, C
    Dayer, P
    Ghanayem, BI
    Blaisdell, J
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1998, 286 (03): : 1490 - 1495
  • [6] Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population
    Hanioka, N.
    Tsuneto, Y.
    Saito, Y.
    Sumada, T.
    Maekawa, K.
    Saito, K.
    Sawada, J.
    Narimatsu, S.
    XENOBIOTICA, 2007, 37 (04) : 342 - 355
  • [7] Two single-tube assays to detect the CYP2C19*2 and CYP2C19*3 alleles.
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    CLINICAL CHEMISTRY, 2001, 47 (06) : A66 - A66
  • [8] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Zalloum, Imad
    Hakooz, Nancy
    Arafat, Tawfiq
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (04) : 4195 - 4200
  • [9] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Imad Zalloum
    Nancy Hakooz
    Tawfiq Arafat
    Molecular Biology Reports, 2012, 39 : 4195 - 4200
  • [10] The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19☆35 and CYP2C19☆2 Alleles
    Chaudhry, Amarjit S.
    Prasad, Bhagwat
    Shirasaka, Yoshiyuki
    Fohner, Alison
    Finkelstein, David
    Fan, Yiping
    Wang, Shuoguo
    Wu, Gang
    Aklillu, Eleni
    Sim, Sarah C.
    Thummel, Kenneth E.
    Schuetz, Erin G.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (08) : 1226 - 1235